Bayer's Strategic Pivot: Legal Challenges and Gene Therapy Ambitions

Bayer's AskBio completes heart failure gene therapy trial recruitment, targets 30% margin by 2030, but faces $5B in 2026 glyphosate payouts and a pivotal Supreme Court hearing.

Bayer is aggressively restructuring its pharmaceutical division, a move that is bringing it into direct conflict with political forces. This strategic push comes at a time when its U.S. subsidiary, AskBio, has reported a significant milestone for a novel gene therapy. However, the company's financial foundation remains under severe pressure, with a pivotal U.S. Supreme Court hearing on the horizon that could shape its future.

Pipeline Progress Amidst Pricing Pressures

Concrete developments are emerging from Bayer's research pipeline. Its subsidiary, AskBio, has completed patient recruitment for the Phase 2 study of its experimental gene therapy for heart failure, known as AB-1002. Initial data from this study, which involves 173 participants, is anticipated in the first half of 2027.

Simultaneously, the company's management is pursuing a new pricing strategy in Europe. Pharma chief Stefan Oelrich is signaling a systemic shift, engaging in talks with European governments to secure higher prices for new drug launches. This initiative is a direct response to an executive order from former U.S. President Donald Trump that pressures pharmaceutical firms to reduce prices in the American market. Notably, Bayer stands apart from 16 other major industry players by not having reached an agreement with Washington to lower U.S. prices in exchange for tariff exemptions.

Ambitious Targets Confront Financial Realities

The clinical advancements are intended to support ambitious mid-term financial goals. The pharmaceuticals unit aims to return to mid-single-digit growth starting in 2027. By 2030, it is targeting an operational margin of approximately 30 percent. The long-term outlook has found favor with investors: the stock has gained a substantial 85.97 percent over a twelve-month horizon and closed at 39.44 euros on Friday.

This operational optimism, however, is tempered by the persistent burden of glyphosate litigation. The company forecasts litigation-related payouts of around five billion euros for 2026 alone, a figure expected to result in deeply negative free cash flow. Consequently, the near-term trajectory for Bayer's shares is heavily dependent on a series of upcoming legal and operational events:

• April 27, 2026: Oral arguments commence before the U.S. Supreme Court concerning the glyphosate litigation complex.
• May 12, 2026: Publication of first-quarter financial results.
• Second half of June 2026: The Supreme Court's ruling is expected. This decision could potentially undermine the legal basis for thousands of future lawsuits.